CFGS
MRTX

Concourse Financial Group Securities’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Concourse Financial Group Securities’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$58 – 2382
2023
Q4 		$58 Hold
1
– – ﹤0.01% 2253
2023
Q3 		$43 Buy
+1
New +$36 ﹤0.01% 2282

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Concourse Financial Group Securities's MRTX Position: Q1 2024 in Review

Concourse Financial Group Securities sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1 share — an estimated $58 sold.

Concourse Financial Group Securities first reported a position in MRTX in Q3 2023 and held it in 2 quarters. The position peaked at $58 in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Concourse Financial Group Securities reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Concourse Financial Group Securities sold 1 Mirati Therapeutics, Inc. Common Stock share in Q1 2024, an estimated $58.
  • Concourse Financial Group Securities first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Concourse Financial Group Securities's Mirati Therapeutics, Inc. Common Stock position peaked at $58 in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Concourse Financial Group Securities's 13F filing for Q1 2024, filed 1 May 2024.